In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rep. Kennedy Supports $200 Million National Neurotechnology Initiative

This article was originally published in The Gray Sheet

Executive Summary

Rep. Patrick Kennedy, D-R.I., is sponsoring the National Neurotechnology Initiative Act, which would provide $200 million in federal funding for brain and nervous system research and development

You may also be interested in...



Advocates Call National Neurotechnology Initiative A Bargain At $200 Million

The neurotechnology industry is gaining congressional support for an envisioned National Neurotechnology Initiative by highlighting its cost-effectiveness

Advocates Call National Neurotechnology Initiative A Bargain At $200 Million

The neurotechnology industry is gaining congressional support for an envisioned National Neurotechnology Initiative by highlighting its cost-effectiveness

Neurotech bill introduced

The National Neurotechnology Initiative Act, H.R. 5989 and S. 2989, is introduced in the House and Senate May 7 to accelerate development of new treatments for brain-related illness or injury by distributing $200 million per year in federal funding to research and other efforts (1"The Gray Sheet" March 17, 2008, p. 7)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025895

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel